Obesity Reduces Vaccine Efficacy: The Role of Lung Immune Cells

New research reveals that obesity significantly impairs the quality and longevity of antibody responses to certain vaccines, particularly against Pseudomonas aeruginosa, while simultaneously triggering a compensatory response from lung tissue-resident memory T cells that may help defend against respiratory infections.

The findings, published in The Journal of Immunology, come from a study conducted in mouse models by researchers at the University of Missouri. The study shows that obesity leads to defects in germinal centers — specialized areas of the immune system where B cells produce antibodies and build immune memory — resulting in weaker and shorter-lived antibody responses to vaccination.

Despite this impairment in antibody production, the vaccine still elicited a strong response from lung tissue-resident memory T cells. These cells, which reside permanently in the lungs and do not circulate in the bloodstream, provided early and critical protection against infection in obese mice — a response not observed in mice on normal or low-fat diets.

“Instead of just trying to boost blood antibody levels, we should intentionally design vaccines that prioritize tissue-resident immunity, ensuring protection directly where pathogens like Pseudomonas enter the body,” said Wendy L. Picking, Ph.D., Professor in the Department of Pathobiology and Integrative Biomedical Sciences at the University of Missouri and lead author of the study.

The research highlights a growing urgency for better vaccines tailored to individuals with obesity, who are at higher risk for severe respiratory infections. Scientists suggest that future vaccine strategies may need to shift focus from enhancing systemic antibody responses to strengthening localized immune defenses in tissues such as the lungs.

Additional evidence supports the broader impact of obesity on vaccine efficacy. Studies have linked obesity to chronic inflammation that disrupts immune cell coordination and compromises lung function, leaving individuals more vulnerable to infections and less protected by vaccines intended to prevent them.

Research on squalene-adjuvanted influenza vaccines in obese mice further demonstrates a dual impact: while immunity may be altered, the vaccine also influences glucose homeostasis, underscoring the complex interplay between metabolism and immune response in the context of obesity.

Experts caution that while these findings are based on animal models, they provide important insights into why traditional vaccines may underperform in populations with obesity and point toward new directions for vaccine design that account for metabolic health.